CM24 combined with Opdivo and chemotherapy showed significant survival benefits in pancreatic cancer patients with CEACAM1 biomarkers. The study reported up to a 90% reduction in risk of death in ...
Opdivo plus chemotherapy improved median OS to 14.3 months versus 10.3 months with chemotherapy alone in Chinese patients with advanced gastric cancers. The OS benefit was consistent across PD-L1 ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback